Bellus Health
Bellus Health Inc. is a clinical-stage biopharmaceutical company based in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. The company's lead candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor and is currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. In addition to its work on chronic cough, Bellus Health is developing KIACTA™, a novel drug for AA amyloidosis, a rare disease causing renal dysfunction, and is also exploring its potential for treating sarcoidosis. Another investigational product, Shigamab™, is being developed as an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, particularly in children. Bellus Health aims to address significant unmet medical needs through its innovative therapies.
Thallion Pharmaceuticals Inc. is a biotechnology company based in Dorval, Canada, that focuses on developing pharmaceutical products for infectious diseases and oncology. Its primary product candidate, Shigamabs, is a dual antibody treatment currently undergoing Phase II clinical trials for Shigatoxin-producing E. coli infections. The company has previously completed four Phase I trials, confirming the safety and tolerability of Shigamabs. In addition to Shigamabs, Thallion is developing TLN-4601, a novel small molecule aimed at treating various cancer types, including solid and liquid tumors. Thallion also possesses the DECIPHER technology platform, which is designed for the genomic discovery of new secondary metabolites from non-pathogenic microorganisms. The company has established a partnership with Laboratoire français du Fractionnement et des Biotechnologies for the commercialization of Shigamabs in several international markets, while retaining rights for North America and other regions. Founded in 1998, Thallion Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc. since 2017.
Innodia is a privately held biopharmaceutical company with the mission of developing and bringing new drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.